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A B S T R A C T
Neuroendocrine tumors (NETs) arise from a variety of anatomic sites and share the capacity for
production of hormones and vasoactive peptides. Because of their perceived rarity, NETs have not
historically been a focus of rigorous clinical research. However, the diagnosed incidence of NETs
has been increasing, and the estimated prevalence in the United States exceeds 100,000
individuals. The recent completion of several phase III studies, including those evaluating
octreotide, sunitinib, and everolimus, has demonstrated that rigorous evaluation of novel agents in
this disease is both feasible and can lead to practice-changing outcomes. The NET Task Force of
the National Cancer Institute GI Steering Committee convened a clinical trials planning meeting to
identify key unmet needs, develop appropriate study end points, standardize clinical trial inclusion
criteria, and formulate priorities for future NET studies for the US cooperative group program.
Emphasis was placed on the development of well-designed clinical trials with clearly defined
efficacy criteria. Key recommendations include the evaluation of pancreatic NET separately from
NETs of other sites and the exclusion of patients with poorly differentiated histologies from trials
focused on low-grade histologies. Studies evaluating novel agents for the control of hormonal
syndromes should avoid somatostatin analog washout periods when possible and should include
quality-of-life end points. Because of the observed long survival after progression of many
patients, progression-free survival is recommended as a feasible and relevant primary end point for
both phase III studies and phase II studies where a delay in progression is expected in the absence
of radiologic responses.
J Clin Oncol 29:934-943. © 2011 by American Society of Clinical Oncology
INTRODUCTION
Neuroendocrine tumors (NETs) arise in diverse an-
atomic locations and are classically associated with
symptoms resulting from the secretion of hormones
or vasoactive peptides into the systemic circulation.
Historically perceived as exceedingly rare, NETs
have recently been shown to be more common than
previously suspected. In an analysis of the Surveil-
lance, Epidemiology, and End Results database, the
estimated annual incidence of carcinoid tumors in
2004 was 5.25 per 100,000 population, and the 29-
year limited duration prevalence in the United States
was estimated to exceed 100,000 individuals.1
Surgical resection alone is often curative in pa-
tients with early-stage disease. However, patients
with advanced disease may suffer from complica-
tions of uncontrolled hormone secretion and usu-
ally succumb to fatal complications caused by
secreted hormones or tumor progression. The NET
Task Force of the National Cancer Institute GI Steer-
ingCommittee was created to encourage clinical and
translational research in NETs and to facilitate the
development and coordination of relevant clinical
trials in this disease. As part of this effort, the task
force convened a clinical trials planning meeting to
identify key unmet needs and to formulate priorities
for future NET studies for the US cooperative group
program. Other key meeting objectives included the
development of recommendations for appropriate
study end points and imaging techniques and stan-
dardization of clinical trial inclusion criteria.
Participants in this day and a half meeting in-
cluded clinical, translational, and laboratory-based
investigators in neuroendocrine cancer as well as
representatives from the patient advocacy commu-
nity, pharmaceutical industry, and the National
Cancer Institute. The meeting was structured to in-
clude brief didactic presentations during an initial
half-day session, summarizing recent developments
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and current questions in the field. Subsequently, participants partici-
pated in breakout sessions where they discussed clinical trial priorities
in specific areas. Recommendations from the breakout sessions were
then brought back to the larger group for consensus on the second day
of the meeting. Ideas and concepts from the meeting were further
developed and refined during subsequent meetings of the NET Task
Force, leading to the key recommendations (Table 1) outlined in this
article. This report is structured to address key issues for clinical trials
in NETs by stating the key recommendations followed by a summary
of the deliberations leading to the recommendation.
Table 1. Key Recommendations From the NET Clinical Trials Planning Meeting
Recommendation
Classification of neuroendocrine tumors
Carcinoid tumors and pancreatic NETs should be examined separately in clinical trials. Stratification of carcinoid tumors by primary site should be considered
in larger, randomized studies.
The American Joint Committee on Cancer staging system for NETs should be used as the staging standard in clinical trials.
A formal assessment of grade or differentiation should be required for clinical trial enrollment; well-differentiated and poorly differentiated NETs should be
studied separately.
Although large-scale, prospective studies specifically enrolling patients with specific molecular subtypes are not currently indicated, useful information
regarding the activity of specific drugs in molecular subtypes can be gained from retrospective analyses of tumors and annotated clinical data.
Adjuvant trials in patients with resected NETs
Adjuvant therapy is not currently indicated in patients with completely resected NETs. Additional data regarding time to recurrence and overall survival of
patients with resected NETs will be necessary to design adequately powered studies in this setting.
Evaluation of therapeutic agents for carcinoid syndrome
Refractory carcinoid syndrome is an unmet medical need. The successful clinical development of new agents for this indication has proven challenging
because of difficulty in selecting appropriate entry criteria and clinical trial end points.
Use of a somatostatin washout in trials of novel agents for carcinoid syndrome should be avoided when possible.
A symptom severity index based on a composite score of flushing and diarrhea would provide an appropriate measure of patient-reported outcomes and
could be used as an end point in trials of novel agents for carcinoid syndrome. Randomized, placebo-controlled studies incorporating such an index, in
conjunction with more general quality-of-life measures, are recommended for the investigation of novel agents in this indication.
Hepatic-directed therapy
Because of the highly selected nature of patients undergoing either hepatic resection or orthotopic liver transplantation, randomized controlled trials
evaluating patient outcomes with these treatment modalities would likely be difficult to perform.
Hepatic artery embolization is commonly performed in patients with unresectable, hepatic-predominant disease. A variety of techniques, including bland
embolization, chemoembolization, and radioembolization, are currently used but have never been compared in a controlled setting. Randomized phase II
trials exploring the relative efficacy and toxicity of these techniques are recommended.
Peptide receptor radiotherapy
Randomized phase III studies comparing peptide receptor radiotherapy to standard systemic therapy are warranted.
Clinical trials of novel systemic agents for advanced NET
Study design and end points
Overall survival is not a practical end point for most advanced NET studies. PFS is recommended as the primary end point for phase III studies, as well as
for phase II studies where a delay in progression is expected in the absence of significant radiologically defined tumor responses.
Randomized phase II studies, requiring disease progression before study entry and using PFS as a primary end point, should be used to screen novel
agents in NETs.
Randomized trials in NETs investigating novel therapies need to account for the potential antitumor activity of somatostatin analogs.
Imaging considerations
Cross-sectional anatomic imaging of the abdomen should be performed with either multiphasic CT or MRI.
Study baseline cross-sectional anatomic imaging should include chest, abdomen, pelvis, and any additional known sites of disease.
Somatostatin scintigraphy should not be used to assess tumor response in clinical trials.
Incorporation of biomarkers
Serial measurements of plasma chromogranin A should be incorporated into prospective clinical trials.
Assessment of tumoral O6-methylguanine–DNA methyltransferase expression is warranted in future studies of alkylating agents.
Imaging with perfusion CT should be considered in future studies of antiangiogenic agents.
Specific recommendations for ongoing and future studies
Advanced carcinoid tumors
Successful completion of the ongoing phase III study of bevacizumab versus interferon in patients with advanced carcinoid tumors (SWOG S0518) may
define the role of bevacizumab in patients with advanced carcinoid tumors.
The results of a phase III study of everolimus plus octreotide versus octreotide alone may define the role of everolimus in patients with advanced
carcinoid tumors.
Randomized studies of tyrosine kinase inhibitors targeting VEGFR should be considered in patients with advanced carcinoid tumors.
Advanced pancreatic neuroendocrine tumors
Sunitinib and other tyrosine kinase inhibitors targeting VEGFR are active in patients with advanced pancreatic NETs.
Everolimus is active in patients with advanced pancreatic NETs. A randomized phase II study comparing everolimus alone with the combination of
everolimus plus bevacizumab in patients with pancreatic NET will build on the recent observation of activity with everolimus alone and may help define
the potential additive activity of bevacizumab in this setting.
In contrast to carcinoid tumors, there is now substantial evidence that pancreatic NETs are sensitive to alkylating agents. Randomized studies assessing the
relative efficacy of streptozocin or temozolomide and assessing the efficacy of temozolomide alone or a temozolomide-based doublet are warranted.
Abbreviations: NET, neuroendocrine tumor; PFS, progression-free survival; CT, computed tomography; MRI, magnetic resonance imaging; SWOG, Southwest
Oncology Group; VEGFR, vascular endothelial growth factor receptor.
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CLASSIFICATION OF NET
Classification by Site of Origin
Carcinoid tumors and pancreatic NETs should be examined sepa-
rately in clinical trials. Although carcinoid and pancreatic NETs often
have nearly identical characteristics on routine histologic evaluation, it
is increasingly clear that these two tumor subtypes have different
biology, respond differently to therapeutic agents, and should be eval-
uated as separate entities in clinical trials. Carcinoid tumors them-
selves may differ in their response to treatment depending on their site
of origin, most commonly the small bowel, appendix, rectum, stom-
ach, and lungs.1,2 Individual clinical trials targeting specific carcinoid
anatomic subgroups may not be feasible as a result of limited patient
numbers. However, stratification of carcinoid tumors by primary site
should be considered in larger randomized studies.
Classification by Tumor Stage
The American Joint Committee on Cancer staging system for NETs
should be used as the staging standard in clinical trials. Several organi-
zations, including the European Neuroendocrine Tumor Society3,4
and the American Joint Committee on Cancer (AJCC), have proposed
staging systems for NETs using the commonly accepted TNM nota-
tion.5 Although these two staging systems are similar for tumors aris-
ing in the luminal gut, they differ for earlier stage tumors arising in the
pancreas or appendix. In pancreatic NETs, for example, the European
Neuroendocrine Tumor Society system incorporates tumor diameter
in its assessment of T stage, whereas the AJCC system incorporates
factors determining tumor resectability. Both systems have been clin-
ically validated and are nearly identical in their definitions of stage IV
disease. Because the AJCC system has been widely adopted for other
malignancies in North America, use of the AJCC system is also recom-
mended for NETs to avoid confusion and to enhance consistency in
clinical trials.
Histologic Classification
A formal assessment of grade or differentiation should be required
for clinical trial enrollment; well-differentiated and poorly differentiated
NETs should be studied separately. A number of often conflicting
histologic and anatomic classification systems have been proposed to
subclassify NETs (Table 2). These systems are inconsistent in their
specific criteria for tumor grading, their reporting of mitotic count,
and their requirements for measurement of proliferation index (Ki-
67). Despite these differences, all commonly used classification sys-
tems reflect the basic observation that NETs comprise a spectrum of
malignancies, ranging from more indolent, well-differentiated tumors
to far more aggressive poorly differentiated ones. As a general rule,
tumors with a high grade (grade 3), a mitotic count of more than 20
per 10 high-powered fields, or a Ki-67 proliferation index of more
than 20% represent highly aggressive malignancies that should be
evaluated apart from more classic carcinoid, islet cell, or well-
differentiated (low- to intermediate-grade) NETs. In large multicenter
studies, central pathology review or pathology auditing would en-
hance consistency in pathology reporting and ensure enrollment of
patients with appropriate tumor histologies.
Molecular Classification
Although large-scale, prospective studies enrolling patients with spe-
cific molecular subtypes are not currently feasible, useful information
regarding the activity of specific drugs in molecular subtypes can be gained
from retrospective analyses of tumors and annotated clinical data. NETs
are associated with a number of inherited syndromes associated with
mutations in well-studied oncogenes and tumor suppressor genes.
These syndromes include multiple endocrine neoplasia types 1 and 2,
von Hippel-Lindau disease, and tuberous sclerosis.7 Patients with
NET with such syndromes may represent subgroups particularly re-
sponsive to novel therapies targeting the underlying genetic defect or
pathway. Characteristic allelic imbalances have also been observed in
sporadic carcinoid and pancreatic NETs. Loss of chromosome 18, for
example, seems to be a characteristic feature of small bowel carcinoid
tumors.8-10 A more detailed understanding of the molecular aberra-
tions in NETs will be increasingly relevant as additional molecularly
targeted therapies are developed. The rigorous analysis of molecular
aberrations and clinical outcomes in annotated biospecimens would











 2  2 Carcinoid, islet cell, pancreatic
(neuro)endocrine tumor
Neuroendocrine tumor, grade 1 Neuroendocrine carcinoma, grade 1
Intermediate grade
(grade 2)
2-20 3-20 Carcinoid, atypical carcinoid,‡
islet cell, pancreatic
(neuro)endocrine tumor




 20  20 Small-cell carcinoma Neuroendocrine carcinoma, grade 3,
small cell




Neuroendocrine carcinoma, grade 3,
large cell
Neuroendocrine carcinoma, grade 3,
large cell
Abbreviations: HPF, high-power field; ENETS, European Neuroendocrine Tumor Society.
HPF  2 mm2; at least 40 fields (at 40 magnification) were evaluated in areas of highest mitotic density. Cutoff values were taken from American Joint
Committee on Cancer staging system (seventh edition).5
†MIB1 antibody; percentage of 2,000 tumor cells in areas of highest nuclear labeling. Cutoff values were taken from American Joint Committee on Cancer staging
system (seventh edition).5
‡The term atypical carcinoid only applies to intermediate-grade neuroendocrine tumor of the lung.
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represent a useful and feasible first step in defining clinically relevant
molecular subgroups of carcinoid and pancreatic NETs.
ADJUVANT TRIALS IN PATIENTS WITH RESECTED NET
Adjuvant therapy is not currently indicated in patients with com-
pletely resected NETs. Additional data regarding time to recurrence
and overall survival (OS) of patients with resected NETs will be nec-
essary to design adequately powered studies in this setting. Whenever
possible, complete surgical resection with curative intent of the pri-
mary tumor should be performed; however, many patients may nev-
ertheless develop disease recurrence. The probability of recurrence
may vary depending on the site and the biologic aggressiveness of the
tumor. However, the design and completion of definitive studies evaluat-
ing adjuvant regimens in patients with fully resected NETs is challenging,
andnoadequatelycontrolledstudieshavebeenperformed.A lack of data
regarding recurrence rates and median time to tumor recurrence after
resection of carcinoid or pancreatic NETs presents a major obstacle to
designing studies of appropriate power and duration. The ongoing
development of tumor registries and databases should help provide
such data, facilitating the development of future adjuvant studies.
Analysis of such data should also help identify patient subgroups at
particularly high risk of recurrence, for example, patients who have
undergone complete resection of hepatic metastases.
EVALUATION OF THERAPEUTIC AGENTS FOR
CARCINOID SYNDROME
Refractory carcinoid syndrome is an unmet medical need. Carci-
noid syndrome is caused by the secretion of serotonin and other
bioactive amines into the systemic circulation and is clinically mani-
fested by flushing, diarrhea, and fibrosis of the right-sided heart valves
and intestinal mesentery. Currently available somatostatin analogs
including octreotide and lanreotide (the latter approved only for ac-
romegaly in the United States) ameliorate symptoms of carcinoid
syndrome.11,12 Over time, however, patients with carcinoid syndrome
may become refractory to somatostatin analogs. A number of novel
somatostatin analogs and serotonin synthesis inhibitors are currently
undergoing clinical evaluation in patients with refractory carcinoid
syndrome. However, the successful clinical development of these
agents has proven challenging, in large part because of difficulty in
selecting appropriate entry criteria and clinical trial end points for
this indication.13
Use of a somatostatin washout in trials of novel agents for carcinoid
syndrome should be avoided when possible. Prior studies of novel
agents for the treatment of carcinoid syndrome have required a soma-
tostatin analog washout period to establish baseline levels of flushing
and diarrhea. A requirement for washout periods is a clear deterrent to
enrollment for patients and may pose an ethical dilemma for physi-
cians. Such a washout may not be necessary to establish efficacy if
study end points are measured at predefined time points (eg, two to
three half-lives after the last dose of prestudy medication) after initia-
tion of investigational therapy.
A symptom severity index based on a composite score of flushing and
diarrhea would provide an appropriate measure of patient-reported out-
comes and could be used as an end point in trials of novel agents for
carcinoid syndrome. Randomized, placebo-controlled studies incor-
porating such an index, in conjunction with more general quality-of-
life measures, are recommended for the investigation of novel agents
in this indication. The evaluation of flushing and diarrhea as separate
end points requires multiple parallel analyses (eg, flushing only, diar-
rhea only, flushing and diarrhea) and necessitates a greater number of
patients because many patients may not have both components of the
classic syndrome. Use of a validated symptom severity index based on
a composite score of flushing and diarrhea would simplify end point
analyses. Additionally, preliminary studies suggest that quality-of-life
measures correlate closely with both flushing and diarrhea frequency
in patients with carcinoid syndrome.14 The European Organisation
for Research and Treatment of Cancer has recently developed a
quality-of-life instrument specifically designed for patients with carci-
noid tumors and NETs (European Organisation for Research and
Treatment of Cancer Quality of Life Questionnaire GI.NET21) that
incorporates questions on disease-specific symptoms.15 Used together
with a more general quality-of-life questionnaire, this may be a useful
tool in future trials. Randomized, controlled studies of novel agents in
patients with hormonal syndrome refractory to somatostatin analogs,
using patient-reported outcome measures, are appropriate and
should be feasible. Although some agents, including somatostatin
analogs, may have effects on both symptom and tumor control, stud-
ies focused on symptom relief should in general be clearly differenti-
ated from studies focused primarily on tumor control (discussed later)
in light of the different end points and different requirements for
trial design.
HEPATIC-DIRECTED THERAPY
Hepatic-directed therapies include hepatic resection, orthotopic liver
transplantation (OLT), and hepatic arterial embolization. These tech-
niques are most often used in patients with hepatic-predominant
disease to improve symptoms.16 OLT has been attempted in patients
with NET who are not candidates for hepatic resection. Although
associated with encouraging 5-year survival rates, OLT has also been
associated with relatively high rates of tumor recurrence, and it has no
clear role in the routine treatment of patients with NET.17 Because of
the highly selected nature of patients undergoing either hepatic resec-
tion or OLT, randomized controlled trials evaluating patient out-
comes with these treatment modalities would likely be difficult
to perform.
Hepatic artery embolization is commonly performed in patients
with unresectable, hepatic-predominant disease. A variety of tech-
niques, including bland embolization, chemoembolization, and ra-
dioembolization, are currently used but have never been compared in
a controlled setting. Randomized phase II trials exploring the relative
efficacy and toxicity of these techniques are recommended. Hepatic
artery embolization has been routinely reported to result in both
tumor responses and improvement in symptoms. Although the addi-
tion of intra-arterial cytotoxic chemotherapy (chemoembolization),
as opposed to bland embolization, has been reported to improve
outcome for patients with pancreatic NETs, the relative benefit of
adding intra-arterial chemotherapy has not been as clearly established
in patients with carcinoid tumors.18 More recent studies have sug-
gested that radioembolization is an effective and potentially less toxic
approach in the short term, although this technique has not been
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formally compared with either chemoembolization or bland emboli-
zation in a prospective fashion.19,20 Given the logistical challenges of
performing randomized studies of these modalities, definitive large-
scale randomized phase III studies may not be feasible. However,
randomized phase II studies are warranted to shed light on the relative
cost, toxicity, and efficacy of newer embolization techniques com-
pared with more standard bland embolization.
PEPTIDE RECEPTOR RADIOTHERAPY
A high prevalence of somatostatin receptor expression among NETs
provides the rationale for peptide receptor–targeted therapy as a treat-
ment modality in patients with inoperable or metastatic disease. The
most frequently used radionuclides for targeted radiotherapy in NETs
are indium (111In), yttrium (90Y), and lutetium (177Lu), which differ
from one another in terms of emitted particles, particle energy, and
tissue penetration.21,22 Both the yttrium- and the lutetium-labeled
compounds have demonstrated promising activity in patients with
NET.23-25 However, many reported studies have had suboptimal
methodology, lacked intent-to-treat analyses, and used nonstandard
end point definitions. Furthermore, no studies have compared the
relative efficacy and toxicity of 177Lu-DOTA-Tyr3-octreotate and 90Y-
DOTA-Tyr3-octreotide.
Randomized phase III studies comparing peptide receptor
radiotherapy with standard systemic therapy are warranted. Pa-
tients enrolling onto such studies should be selected based on
somatostatin expression. Recent data suggesting that octreotide
alone has antitumor efficacy in midgut carcinoid tumors make it
both feasible and relevant to randomly assign patients prospec-
tively to either radiopeptide therapy or treatment with unlabeled
octreotide in midgut tumors and perhaps also in other carcinoid
tumors.26 In pancreatic NETs, appropriate control groups could
include unlabeled octreotide or potentially also everolimus,
sunitinib, or streptozocin-based chemotherapy.27-30
CLINICAL TRIALS OF NOVEL SYSTEMIC AGENTS FOR
ADVANCED NET
The unique clinical characteristics of NETs present specific chal-
lenges to the design and successful completion of clinical trials.
Among these challenges are the selection of appropriate end
points, use of reproducible imaging modalities, and incorporation
of biomarkers. A number of systemic agents have recently been
evaluated for the treatment of advanced NETs. Among the most
promising of these therapies are somatostatin analogs, temozolo-
mide, vascular endothelial growth factor (VEGF) pathway inhibi-
tors, and mammalian target of rapamycin (mTOR) inhibitors. The
continued rigorous evaluation of these and other promising agents
in future trials is encouraged and is likely to lead to significant
advances in the treatment of patients with NETs.
Study Design and End Points
OS is not a practical end point for most advanced NET studies.
Improving OS is clearly a primary goal in developing novel agents. In
selected patients with NETs, particularly those with highly refractory
disease or for whom survival duration is otherwise expected to be
limited, trials using OS as a primary end point may be feasible. How-
ever, the long survival after progression and the wide variability of
salvage regimens in many patients with NETs preclude the use of OS as
a practical end point in most studies. For example, in the Placebo-
Controlled Prospective Randomized Study on the Antiproliferative
Efficacy of Octreotide LAR in Patients With Metastatic Neuroendo-
crine Midgut Tumors (PROMID), where octreotide was studied in
the first-line setting among patients with midgut carcinoid tumors,
median survival after progression was estimated to be more than 60
months.31 In an everolimus study enrolling patients with progressive
carcinoid tumors, survival after progression was estimated to be more
than 12 months.32 Similarly, in recently reported studies of sunitinib
and everolimus among patients with progressive pancreatic NETs,
median survival times after progression were also both greater than 12
months.27,28 In this situation, use of OS as a primary end point may be
complicated by treatment after progression. Postprogression treat-
ment (either from a planned cross-over design using the investiga-
tional therapy or with investigator-selected treatment) poses no
significant scientific challenges in studies using progression-free sur-
vival (PFS) as a primary end point and is attractive from both an
ethical and feasibility standpoint. In contrast, if OS is used as a primary
end point, the incorporation of cross over may significantly reduce the
probability of observing a treatment benefit. OS also tends to require a
larger sample size. For example, when the hazard ratio is assumed to be
the same for both end points, the time to observe the same number of
OS events as PFS events is much longer, requiring either much longer
study follow-up or an increased sample size to reach a study conclu-
sion in a shorter time period. Moreover, if the same absolute improve-
ment in PFS is propagated into improvement in OS, the relative effect
size in a disease with longer baseline OS would be smaller, translating
into a need for a greater number of patients.33,34
In general, PFS is recommended as the primary end point for phase
III studies, as well as for phase II studies where a delay in progression is
expected in the absence of significant radiologically defined tumor re-
sponses. Many recent phase II studies of novel agents in NETs have
reported low tumor response rates, resulting in a perception that
the evaluated agents had little or no antitumor activity in this
setting. However, recent randomized studies of octreotide,31
sunitinib,28 and everolimus27 suggest that tumor response rate may
not be an optimal marker for antitumor activity in NETs. Although
associated with only modest radiologic tumor response rates, treat-
ment with these agents resulted in significant improvements in PFS
when compared with placebo or best supportive care in con-
trolled studies.
Using PFS as an end point in NET trials may present its own
challenges. Investigator bias is a potential concern, particularly when
cross-over designs are used. Blinded trial designs or central review for
progression determination can be used to mitigate this concern.35
Each of these options, however, has its own limitations. Blinded trials
may be difficult to conduct when adverse event profiles differ dramat-
ically between the treatment arms. Central review may be logistically
difficult and can be particularly challenging in NETs, where imaging
characteristics are often highly variable. Significant discrepancies be-
tween local and central review have recently been reported in a large
randomized trial of everolimus in carcinoid tumors (RAD001 in Ad-
vanced Neuroendocrine Tumors [RADIANT] -2). Such discrepancies
can contribute to the phenomenon of informative censoring, which
Kulke et al
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may significantly reduce the power of a study.36 Use of real-time
central review in trials using PFS as a primary end point may help
overcome the obstacles caused by discrepancies between local and
central review. Pilot studies using real-time central review in NET
trials are encouraged. The incorporation of end points beyond radio-
logic progression, such as quality-of-life end points, is also encouraged
to provide further information on the potential clinical benefit of
novel agents in NETs.
Randomized phase II studies, requiring disease progression before
study entry and using PFS as a primary end point, should be used to screen
novel agents in NETs when the primary benefit is expected to be delay in
progression. Because of the lack of reliable historical control data for
patients with NETs, single-arm trials are not likely to provide sufficient
evidence of activity to guide the design of phase III trials. Disease
heterogeneity and selection bias in existing studies suggest that
randomized designs should be prioritized in NET studies. A par-
ticularly vexing issue in prior phase II studies has been the wide
variability in the requirement (or lack thereof) for disease progres-
sion before study entry. When PFS is the primary end point, a
general requirement for clinical evidence of disease progression
within 12 months before study entry, as has been required in
recently completed phase III studies, is highly encouraged in future
phase II studies; this requirement should also facilitate cross-study
comparisons. When feasible, randomized phase II studies using a
PFS end point should be performed to more accurately explore
efficacy among novel therapeutic agents.
Randomized trials in NETs should either include somatostatin an-
alogs in all arms or stratify for the concurrent administration of soma-
tostatin analogs. In a recent study, 85 patients with advanced midgut
NETs and predominantly low-volume disease were randomly as-
signed to receive treatment with octreotide long-acting release or
placebo (Table 3). Patients randomly assigned to the octreotide arm
had a significantly longer median time to progression than patients
assigned to the placebo arm (14.3 v 6 months, respectively; P  .01) at
a planned interim analysis, leading to early termination of the study.31
Given the evidence of antitumor activity associated with somatostatin
analogs in this study, concurrent use of somatostatin analogs should
be formally taken into account in NET studies. Randomized studies
examining whether other somatostatin analogs also improve PFS are
of potential future interest, particularly in patients with pancreatic
NETs or carcinoid tumors not of midgut origin. A randomized trial
evaluating the effect of lanreotide versus placebo on PFS in patients
with nonfunctioning NETs is currently ongoing.
Table 3. Randomized Phase III Trials in Advanced NETs
Study and Regimen
Total No.






Moertel et al30 105
Streptozocin  doxorubicin 69 20.0 Nonstandard* .001
Streptozocin  fluorouracil 45 6.9
Raymond et al28 171
Sunitinib 9 11.4 RECIST  .001
Placebo 0 5.5
Yao et al27 410
Everolimus 11.0 RECIST  .001
Placebo 4.6
Carcinoid tumors
Rinke et al31 90
Octreotide LAR 2 14.3 WHO  .001
Placebo 2 6.0
Pavel et al32 429
Everolimus  octreotide LAR 16.4 RECIST .026





Bevacizumab  octreotide LAR RECIST









Abbreviations: NETs, neuroendocrine tumors; ORR, overall response rate; PFS, progression-free survival; TTP, time to progression; RECIST, Response Evaluation
Criteria in Solid Tumors; LAR, long-acting release.
Nonstandard includes computed tomography scan, radioisotope scan, physical exam, or hormonal response.
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Imaging Considerations
Cross-sectional anatomic imaging of the abdomen should be per-
formed with either multiphasic computed tomography or magnetic reso-
nance imaging. NETs are highly vascular and enhance intensely with
intravenous contrast during the early arterial phases of imaging, with
washout during the delayed portal venous phase. In other phases,
however, tumor metastases may appear isodense with liver and, as a
consequence, may be poorly visualized. The dramatic variation in the
appearance of NET metastases with different contrast phases can
create significant challenges in evaluating tumor response or progres-
sion during clinical trials. Multiphasic computed tomography (CT),
which includes both arterial and portal venous phase images, often
provides a more consistent assessment of tumor burden in patients
with NETs and is encouraged for clinical trials. Magnetic resonance
imaging (MRI) is a reasonable alternative for imaging NETs because
lesions can be visualized without contrast in T1 and T2 sequences,
reducing the variability sometimes seen with CT-based imaging re-
sults.37,38 One limitation of MRI scanning is that it may be less sensi-
tive than CT scan for imaging extrahepatic disease.
Baseline cross-sectional anatomic imaging for clinical trials should
include chest, abdomen, pelvis, and any additional known sites of disease.
Although the liver is often the predominant site of metastases in
patients with NETs, disease may occur in the chest and other sites.
Therefore, baseline imaging for clinical trials should include imaging
of the chest, abdomen, and pelvis, with the choice of follow-up imag-
ing individualized by patient.
Somatostatin scintigraphy should not be used to assess tumor re-
sponse in clinical trials. [111In-DTPA0]octreotide was developed for
nuclear scintigraphy of NETs expressing somatostatin receptors 2 and
5. Whole-body nuclear imaging using this approach may establish the
presence or absence of somatostatin receptors in the tumor, identify
occult sites of metastases, and help characterize otherwise indetermi-
nate lesions found on anatomic imaging. However, because [111In-
DTPA0]octreotide uptake is a function of both somatostatin receptor
status and tumor bulk, changes in intensity of uptake should not be
used as a standard to assess tumor response to therapeutic agents.
Incorporation of Biomarkers
Serial measurements of plasma chromogranin A should be incorpo-
rated into prospective clinical trials. Both plasma chromogranin A and
24-hour urinary 5-hydroxyindoleacetic acid levels have been evalu-
ated in prior NET studies as surrogate markers of response. Although
5-hydroxyindoleacetic acid levels are generally elevated in patients
with metastatic midgut carcinoid tumors, they are not as useful in
patients with foregut (bronchial, gastric) or hindgut (rectal) carcinoid
tumors or in most patients with pancreatic NETs, which do not secrete
serotonin. Chromogranin A (CgA) is a 49-kDa protein that is con-
tained in the neurosecretory vesicles of NET cells and is commonly
detected in the plasma of patients with endocrine neoplasms.39,40
Elevated plasma CgA levels have been associated with poor overall
prognosis in patients with NETs.40 Additionally, early decreases in
CgA have been associated with favorable treatment outcomes in some
studies.29,41 However, the prognostic value and predictive value of
CgA have not been widely validated and may also be therapy depen-
dent. Validation of CgA as a prognostic and potentially predictive
biomarker in future studies is warranted.
Assessment of tumoral O6-methylguanine–DNA methyltransferase
expression is warranted in future studies of alkylating agents. The sen-
sitivity of tumor cells to alkylating agents, including temozolomide,
has been associated with decreased levels of the DNA repair enzyme
O6-methylguanine-DNA methyltransferase (MGMT), which, through
its ability to restore DNA to its normal form, can prevent chemotherapy-
induced cell death.42 MGMT deficiency seems to be more common in
pancreatic NETs than in carcinoid tumors, potentially explaining the
greater sensitivity of pancreatic NETs to treatment with the alkylating
agents streptozocin or temozolomide and raising the possibility of
using MGMT expression as a predictive marker in future studies of
these tumors.43
Imaging with perfusion CT should be considered in future studies of
antiangiogenic agents. Recent studies evaluating VEGF pathway in-
hibitors in NET have shown treatment-associated decreases in tumor
blood flow as measured by dynamic contrast-enhanced MRI and
perfusion CT. Moreover, in recent phase II studies of bevacizumab or
bevacizumab and everolimus in carcinoid tumors, early decreases in
tumoral blood flow were associated with improved clinical out-
comes.44,45 Assessment of tumor blood flow as a potential predictive
marker of response is warranted in future studies evaluating angiogen-
esis inhibitors in NET.
SPECIFIC RECOMMENDATIONS FOR ONGOING AND FUTURE
STUDIES OF SYSTEMIC THERAPY IN ADVANCED NET
Advanced Carcinoid Tumors
Successful completion of the ongoing phase III study of bevacizumab
versus interferon in patients with advanced carcinoid tumors (Southwest
Oncology Group trial S0518) may define the role of bevacizumab in
patients with advanced carcinoid tumors. In an initial randomized,
run-in, phase II trial, patients with advanced carcinoid tumors were
randomly assigned to treatment with bevacizumab or pegylated inter-
feron alfa-2b.44 Clinical activity of bevacizumab was evidenced by a
response rate of 18% and an improved PFS rate at week 18 (95% v 68%
with interferon). These encouraging results led to the development of
a randomized phase III study led by the Southwest Oncology group
(S0518), in which patients are randomly assigned to receive either
interferon alfa-2b or bevacizumab in addition to octreotide, with a
primary end point of PFS (Table 3). The results of this study may
strongly influence whether bevacizumab is incorporated into future
trials of advanced carcinoid tumors.
The results of a phase III study of everolimus plus octreotide versus
octreotide alone may define the role of everolimus in patients with ad-
vanced carcinoid tumors. mTOR is a serine-threonine kinase impli-
cated in the regulation of cell growth, proliferation, and apoptosis
through modulation of the cell cycle. A promising response rate of
17% in patients with advanced carcinoid tumors was observed in a
single-center study evaluating the mTOR inhibitor everolimus in
combination with depot octreotide.46 Everolimus, in combination
with octreotide, was subsequently taken forward in a randomized
phase III study and compared with placebo plus octreotide
(RADIANT-2). The complete results of this study, when available,
may help further define the potential role of everolimus in patients
with advanced carcinoid tumors.
Randomized studies of tyrosine kinase inhibitors targeting VEGF
receptor should be considered in patients with advanced carcinoid tu-
mors. Three tyrosine kinase inhibitors (sunitinib, sorafenib, and pa-
zopanib), all with demonstrated inhibitory activity for the VEGF
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receptor tyrosine kinases, have been evaluated in patients in advanced
carcinoid tumors in prospective phase II studies.47-49 Although these
agents have consistently been associated with higher Response Evalu-
ation Criteria in Solid Tumors (RECIST) –defined tumor response
rates in advanced pancreatic NETs than in carcinoid tumors, PFS
duration in the carcinoid cohorts has been encouraging, supporting
the evaluation of these or similar tyrosine kinase inhibitors in the
randomized setting in patients with advanced carcinoid tumors.
Advanced Pancreatic NETs
Sunitinib and other tyrosine kinase inhibitors targeting VEGF re-
ceptors are active in patients with advanced pancreatic NETs. Consis-
tent, if relatively modest, tumor responses have been reported in
prospective phase II trials evaluating sunitinib, sorafenib, or pazo-
panib in patients with advanced pancreatic NETs.47-49 The activity of
sunitinib in advanced pancreatic NETs has been further evaluated in
an international placebo-controlled study. This study was discontin-
ued before the first planned interim analysis after the enrollment of
170 patients and the observation of 85 PFS events. Among patients
evaluable for investigator-based response or progression, treatment
with sunitinib was associated with a median PFS of 11.4 months, as
compared with a PFS of 5.5 months in the placebo arm (hazard ratio,
0.41; 95% CI, 0.19 to 0.89; P  .01).28
Everolimus is active in patients with advanced pancreatic NETs. In
a multinational phase II study (RADIANT-1) enrolling 160 patients
with advanced pancreatic NETs and evidence of RECIST-defined
progression after chemotherapy, treatment with everolimus was asso-
ciated with an overall response rate of 9% and a disease control rate of
72%.41 A subsequent randomized phase III study in 410 patients with
progressive advanced pancreatic NETs (RADIANT-3) demonstrated
a significant improvement in PFS associated with everolimus com-
pared with placebo (11 v 4.6 months, respectively; hazard ratio, 0.35;
95% CI, 0.27 to 0.45; P  .01).27
A randomized phase II study comparing everolimus alone with the
combination of everolimus and bevacizumab in patients with pancreatic
NETs will build on the recent observation of activity with everolimus
alone and may help define the potential additive activity of bevacizumab
in pancreatic NETs. mTOR is a downstream mediator of VEGF
signaling. In a recently completed phase II study, the combination of
everolimus and bevacizumab was shown to be well tolerated and
associated with an overall tumor response rate of 26% in patients with
advanced NETs. On the basis of these results, the Cancer and Leuke-
mia Group B 80701 trial will evaluate everolimus or everolimus plus
bevacizumab in patients with advanced pancreatic NETs, using a
randomized phase II design. A similar design could be also be consid-
ered in patients with advanced carcinoid tumors, depending on the
results of RADIANT-2, which randomly assigned patients with ad-
vanced carcinoid tumors to receive either everolimus and octreotide
or octreotide alone.
Randomized studies assessing the relative efficacy of streptozocin or
temozolomide and assessing the efficacy of temozolomide alone or a
temozolomide-based doublet are warranted in patients with pancreatic
NETs. In contrast to carcinoid tumors, there is now substantial
evidence that pancreatic NETs are sensitive to alkylating agents. Al-
though cytotoxic chemotherapy is associated with only modest activ-
ity in patients with advanced carcinoid tumors, a randomized trial
comparing streptozocin/doxorubicin to streptozocin/fluorouracil
demonstrated improved survival associated with streptozocin/doxo-
rubicin in patients with pancreatic NETs. Streptozocin is the only US
Food and Drug Administration–approved therapy for patients with
advanced pancreatic NETs.30 Traditional streptozocin-based regi-
mens used for pancreatic NETs include streptozocin/fluorouracil,
streptozocin/doxorubicin,andathree-drugcombinationofstreptozocin/
doxorubicin/fluorouracil.29 However, the widespread acceptance of
streptozocin for this indication has been limited by concerns regard-
ing toxicity.
Recent prospective and retrospective studies have suggested that
regimens incorporating the oral alkylating agent temozolomide may
be similar in efficacy to streptozocin-based regimens in pancreatic
NETs.19-21 In one retrospective series, for example, temozolomide-
based therapy was associated with an overall response rate of 34% in
patients with pancreatic NETs.43 An adequately powered study com-
paring streptozocin and temozolomide-based therapy may not be
feasible. However, a randomized phase II study would be beneficial to
estimate both the activity and relative toxicities of these regimens. Addi-
tional uncertainty surrounds the relative activity of temozolomide as a
single agent or in combination with other therapeutic agents. An assess-
ment of the antitumor activity and toxicity of temozolomide alone or a
temozolomide-based doublet should be incorporated into such a study.
SUMMARY
Despite early concerns regarding the ability to accrue patients and
complete large randomized trials, ongoing or recently completed
studies of bevacizumab, sunitinib, octreotide, lanreotide, and everoli-
mus have demonstrated the feasibility of rigorous evaluations of novel
antitumor therapies in patients with NETs. Therapies targeting hor-
monal symptoms are of equal importance given their potential
effects on patient quality of life, and well-designed clinical trials
with clearly defined efficacy criteria will be critical in accelerating
the development of such agents. The development of standardized
histologic and staging criteria should enhance the selection of
appropriate patients for clinical studies. Randomized phase II trial
designs, using PFS end points, are encouraged to more rapidly
identify promising new agents to bring forward for definitive eval-
uation in this disease.
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3. Rindi G, Klöppel G, Alhman H, et al: TNM
staging of foregut (neuro)endocrine tumors: A con-
sensus proposal including a grading system. Vir-
chows Arch 449:395-401, 2006
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